Perspective on the current state of the LRRK2 field

JM Taymans, M Fell, T Greenamyre, WD Hirst… - npj Parkinson's …, 2023‏ - nature.com
Almost 2 decades after linking LRRK2 to Parkinson's disease, a vibrant research field has
developed around the study of this gene and its protein product. Recent studies have begun …

Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives

J Hu, D Zhang, K Tian, C Ren, H Li, C Lin… - European Journal of …, 2023‏ - Elsevier
Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

[HTML][HTML] Mechanisms of glucocerebrosidase dysfunction in Parkinson's disease

D Chatterjee, D Krainc - Journal of molecular biology, 2023‏ - Elsevier
Beta-glucocerebrosidase is a lysosomal hydrolase, encoded by GBA1 that represents the
most common risk gene associated with Parkinson's disease (PD) and Lewy Body …

The R1441C-Lrrk2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner in mice

RL Wallings, K McFarland, HA Staley… - Science Translational …, 2024‏ - science.org
Age is the greatest risk factor for many neurodegenerative diseases, yet immune system
aging, a contributor to neurodegeneration, is understudied. Genetic variation in the LRRK2 …

Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson's disease

CEG Leyns, A Prigent, B Beezhold, L Yao… - npj Parkinson's …, 2023‏ - nature.com
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are progressive
neurodegenerative diseases characterized by the accumulation of misfolded α-synuclein in …

A potential patient stratification biomarker for Parkinson´ s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells

Y Naaldijk, B Fernández, R Fasiczka, E Fdez… - npj Parkinson's …, 2024‏ - nature.com
Parkinson´ s disease (PD) is a common neurodegenerative movement disorder and leucine-
rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention …

ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages

RL Wallings, JR Mark, HA Staley, DA Gillett… - … Therapy Nucleic Acids, 2023‏ - cell.com
Genetic variation around the LRRK2 gene affects risk for both familial and sporadic
Parkinson's disease (PD). LRRK2 levels have become an appealing target for potential PD …

The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's disease

S Strader, AB West - Biochemical Society Transactions, 2023‏ - portlandpress.com
The accumulation of aggregated α-synuclein in susceptible neurons in the brain, together
with robust activation of nearby myeloid cells, are pathological hallmarks of Parkinson's …

Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations

A Labrador-Garrido, S Zhong, L Hughes… - Frontiers in Cellular …, 2023‏ - frontiersin.org
Introduction Heterozygous mutations in GBA1, which encodes the lysosomal hydrolase
glucocerebrosidase (GCase), are a common risk factor for the neurodegenerative movement …

GBA1 and The Immune System: A Potential Role in Parkinson's Disease?

ZAM Al-Azzawi, S Arfaie… - Journal of Parkinson's …, 2022‏ - journals.sagepub.com
It is clear that the immune system and inflammation have a role in Parkinson's disease (PD),
including sporadic PD and some genetic forms such as LRRK2-associated PD. One of the …